scholarly journals Successful salvage high-dose chemotherapy and autologous stem-cell transplantation in HIV-related germ-cell tumor

2009 ◽  
Vol 20 (11) ◽  
pp. 1900-1901 ◽  
Author(s):  
M. Hentrich ◽  
X. Schiel ◽  
A. Niedermeier ◽  
L. Lutz ◽  
R. Rupec ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Germ Cell ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Germ Cell Tumor ◽  
High Dose Chemotherapy ◽  
Cell Tumor ◽  
High Dose

scholarly journals Autologous Stem Cell Transplantation in Testicular Germ Cell Tumor—Preliminary Experience from a Single Center

2021 ◽  
Vol 10 (02) ◽  
pp. 97-101
Author(s):  
Gangothri Selvarajan ◽  
Perumal Kalaiyarasi Jayachandran ◽  
Arun Kumar Rajan ◽  
Sivashree Kesana ◽  
Krishnarathinam Kannan ◽  
...  
Keyword(s):  
Stem Cell ◽  
Complete Remission ◽  
Stem Cell Transplantation ◽  
Germ Cell ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Germ Cell Tumor ◽  
Cell Tumor ◽  
High Dose ◽  
Solid Organ

Abstract Background Germ cell tumor (GCT) of the testis is one of the highly curable solid organ malignancies. Those who experience relapse after platinum-based chemotherapy can be salvaged with systemic therapy followed by high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT). Complete remission can be obtained in approximately 50 to 60% of patients treated with HDCT. Our experience reports the efficacy and safety of HDCT followed by ASCT in relapsed GCT. Methods Analysis of patient records (2012–2019) showed that three patients had received HDCT and ASCT. Results All the three patients were treated with BEP (bleomycin, etoposide, and cisplatin) as first-line therapy. HDCT was done in Case 1 after third-line salvage and in other two patients after second-line salvage chemotherapies. High-dose carboplatin and etoposide were used as conditioning regimen. Granulocyte colony-stimulating factor was used for the mobilization of stem cells. After ASCT, complete remission was documented in all the patients. All were alive and disease-free till the last follow-up. Grade ¾ toxicities including myelosuppression, diarrhea, and mucositis were observed in all three patients. Conclusion This is the first report from India on HDCT with ASCT in GCT. HDCT/ASCT seems to be feasible, safe, and effective in relapsed testicular GCTs.

scholarly journals Melphalan, Etoposide, and Carboplatin Megatherapy with Autologous Stem Cell Transplantation in Children with Relapsing or Therapy-Resistant Extracranial Germ-Cell Tumors—A Retrospective Analysis

Cancers ◽  
2020 ◽  
Vol 12 (12) ◽  
pp. 3841
Author(s):  
Marek Ussowicz ◽  
Monika Mielcarek-Siedziuk ◽  
Jakub Musiał ◽  
Mateusz Stachowiak ◽  
Jadwiga Węcławek-Tompol ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Germ Cell ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Germ Cell Tumors ◽  
High Dose Chemotherapy ◽  
Observation Time ◽  
High Dose ◽  
Line Chemotherapy

Pediatric germ cell tumors (GCTs) are a group of chemosensitive malignancies with a 90% curability rate. We report a series of children with relapsing or therapy-resistant GCT treated with melphalan–etoposide–carboplatin high-dose chemotherapy (HDCT) and autologous stem cell transplantation. This consisted of 18 children, either with GCTs after relapse (nine patients) or with an unsatisfactory response to first-line chemotherapy (nine patients), who underwent HDCT. The HDCT regimens MEC1 (carboplatin 1500 mg/m2, etoposide 1800 mg/m2, and melphalan 140 mg/m2) and MEC2 (carboplatin 800 mg/m2, etoposide 800 mg/m2, and melphalan 140 mg/m2) were each used in nine patients. The median observation time was 81 months, the 5-year overall survival (OS) was 76%, and the event-free survival (EFS) was 70.8%. Non-relapse mortality was 0%, and four patients died after HDCT due to progression of the malignancy. No difference in OS or EFS was noted between the MEC1 and MEC2 protocols. The 5-year OS and 5-year EFS were higher in children treated with autologous stem cell transplantation before the age of four years. The presence of metastatic disease or time of HDCT consolidation during first/subsequent line chemotherapy did not affect patient survival. The melphalan–etoposide–carboplatin protocol is feasible in pediatric GCT, but is associated with potentially life-threatening complications. In conclusion, the use of HDCT must be examined in well-designed clinical trials, and the identification of patients who can benefit from this approach is critical to avoid overtreatment.

High-dose chemotherapy and autologous stem cell transplantation in refractory/metastatic nonseminomatous germ cell-tumors: A retrospective study of the Turkish Oncology Association.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e15623-e15623
Author(s):  
Mustafa Ozturk ◽  
Fikret Arpaci ◽  
Sukru Ozaydin ◽  
Nuri Karadurmus ◽  
Evren Ozdemir ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Testicular Cancer ◽  
Germ Cell ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Combination Chemotherapy ◽  
Germ Cell Tumors ◽  
High Dose Chemotherapy ◽  
High Dose

e15623 Background: Testicular cancer is a chemosensitive tumor that may be curable even in relapsed disease. Those patients who do not respond to standard combination chemotherapy or relaps may be treated with high-dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT) as salvage therapy. Methods: Eighty five patients that received HDC and ASCT between Feb 1993 - Dec 2012 in different university clinics of Turkey were retrospectively reviewed and evaluated. Results: Median age of the patients was 24 (range: 11-54 years) and 63 patients (74,1%) had stage III, 21 (24,7%) had stage II disease at initial diagnosis. The primary tumor location was testis in 71 patients (83,5%), and 14 patients (16,5%) had extragonadal region origin. Evaluation of metastatic focuses before HDC and ASCT was as follows: Liver metastasis (n = 23, 27.05%), lung involvement (n = 23, 27.05%) and multiorgan involvement (n =14, 16.47%) and other metastatic involvements (n=4, 4.7%). ICE (ifosfamide, carboplatin, etoposide) regimen was performed as HDC in all patients. Median follow-up was 59 (range: 8-218) months. Pre-ASCT patients’ condition was complete remission (n=28, 32.9%), partial remission (n=36, 42.4%) and never in CR (n=21, 24.7%) respectively. 32 patients (37.6%) relapsed or progressed within 1 year after HDC and ASCT median relaps was time 3 months (range: 0.3 - 36.13). Transplant related mortality was %3.5 and 3 patients died within the engraftment period after HDC. Five-year overall survival rate was 59.7%. Conclusions: HDC and ASCT is an effective and safe approach for patients with metastatic and refractory germ cell testicular cancer patients that do not respond to standard combination chemotherapy.

scholarly journals Successful Treatment with High-Dose Chemotherapy Followed by Autologous Stem-Cell Transplantation in a Patient with Metastatic Germ Cell Tumor

2021 ◽  
pp. 998-1003
Author(s):  
Jung Min Lee ◽  
Byung Woog Kang ◽  
Man-Hoon Han ◽  
Dong Won Baek
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Germ Cell ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Successful Treatment ◽  
Disease Free Survival ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Poor Risk

Although testicular germ cell tumors (GCTs) are known to curable disease even in cases with metastatic disease, patients in intermediate or poor-risk group may experience disease progression or refractory to the initial chemotherapy and needed second-line therapy. Long-term disease-free survival was unsatisfactory in relapsed/refractory patients with poor-risk factors and clinical trials for those patients are still insufficient. High-dose chemotherapy (HDCT) with stem-cell rescue may be an effective alternative for conventional chemotherapy-resistant patients who are eligible for transplantation. Herein, we present successful treatment experience with HDCT followed by autologous stem-cell transplantation in a severely ill patient with heavily pretreated metastatic GCT.

scholarly journals Use of high-dosage chemotherapy with autologous hematopoietic stem cell transplantation as a first-line therapy for the patients with poor-prognosis testicular tumors

2005 ◽  
Vol 62 (3) ◽  
pp. 213-218
Author(s):  
Slobodan Marjanovic ◽  
Snezana Cerovic ◽  
Goran Brajuskovic
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Germ Cell ◽  
Cell Transplantation ◽  
Germ Cell Tumor ◽  
Poor Prognosis ◽  
Cell Tumor ◽  
High Dose ◽  
First Line ◽  
Hematopoietic Stem

Background. High-dose chemotherapy followed by hematopoietic stem cell support can be used as a first-line treatment in patients with germ-cell tumor (GCT) with poor prognosis. Long-term survival rate is attained in 50% of these patients. The aim of this paper was to present the experience at the Department of Hematology, Military Medical Academy, with high-dose cytostatic therapy as first-line chemotherapy in GCT patients with poor prognosis. Methods. Between 1997 and 2003, five patients with high-risk germ-cell tumors were treated with high-dosage chemotherapy followed by an autologous stem cell transplantation. All the patients were with non-seminomatous germ-cell tumors with mixed histology, and one was with extragonadal retroperitoneal germ-cell tumor. Results. The follow-up period ranged from 8 to 33 months. Three patients achieved complete remision, two patients only partial remision, and one was not followed-up. One patient was with residual tumor resection, using retroperitoneal lymphadenectomy, after autologous stem cell transplantation. All the patients were treated according to standard protocols. Conclusion. Early high-dose chemotherapy associated with hematopoietic stem cell support as a first-line treatment in the patients with germ-cell tumor with a poor prognosis, represented an efficient treatment modality.

Sign in / Sign up

Export Citation Format

Share Document